Replies to post #150 on InSite Vision Inc. (fka INSV)

[The Rainmaker]

They were on AMEX until last April....I'm looking more for either Bausch & Lomb, Pfizer or Inspire to buy out INSV in the $1.50-$2.50 range. Unless that Piper Jaffrey initiative comes up with a scenario where INSV buys out another late stage drug or company with a rich potential drug pipeline then back to NASDAQ or AMEX they might go.

[Ely]

ALAMEDA, Calif.--(Business Wire)--
InSite Vision Incorporated (NYSE AMEX: ISV) today announced that the NYSE AMEX
Listings Qualifications Panel (the "Panel") has denied the company`s appeal,
affirming the previous decision to delist InSite Vision's common stock from the
NYSE AMEX LLC* (the "Exchange") effective with the open of trading business on
April 20, 2009.

Upon delisting from the Exchange, the company expects that its common stock will
be eligible for trading on the Over-the-Counter Bulletin Board (OTCBB) or the
Pink OTC Markets, Inc. InSite Vision will notify investors of trading venue
information for its common stock once such information is available.

"InSite Vision possesses solid fundamentals, with a revenue-generating
commercial product, a late-stage product candidate in development, a proven
platform technology and a clear and well-defined strategy in place. While we are
disappointed with the outcome of this hearing, we remain focused on the
execution of our business objectives," said Louis Drapeau, InSite Vision`s Chief Executive Officer.